Business Context and Reporting Period
This Form 8-K reports on the results of an Extraordinary General Meeting held by Zura Bio Limited on June 1, 2023. The meeting addressed shareholder approval for a private placement of equity, specific equity compensation for the Non-Executive Chairman, and an amendment to the company's 2023 Equity Incentive Plan (EIP).
Key Financial Metrics and Capital Structure
The filing details a capital raise rather than operational financial performance metrics such as revenue or profit.
- Private Placement Proceeds: The approved "Second Placement" involves the issuance of 15,073,530 Ordinary Shares (including shares from pre-funded warrants) for consideration of approximately $64 million.
- Total Placement Context: This follows a prior issuance of 3,750,000 shares for approximately $16 million on May 1, 2023. Combined, these issuances exceed 20% of outstanding shares, triggering Nasdaq shareholder approval requirements.
- Outstanding Shares: As of the May 3, 2023 record date, there were 31,802,155 Class A ordinary shares issued and outstanding.
- Equity Incentive Plan: The EIP was amended to increase the share reserve by an additional 5,564,315 Ordinary Shares.
Material Changes and Voting Results
Shareholders approved three key proposals with overwhelming support:
- Private Placement Proposal: Approved with 18,511,602 votes for, 481 against, and 6 abstentions. The closing is expected on June 5, 2023.
- Equity Compensation Proposal: Approved to issue 117,647 shares and grant options for 1,130,000 shares to Non-Executive Chairman Amit Munshi. Voting results: 21,823,616 for, 1,400 against, 0 abstentions.
- EIP Amendment Proposal: Approved to increase the share pool for future grants. Voting results: 21,822,290 for, 2,726 against, 0 abstentions.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the expected closing of the Second Placement on June 5, 2023. Management notes that actual results may differ materially due to risks and uncertainties. The filing does not provide specific operational guidance, revenue forecasts, or liquidity projections beyond the capital raise details.
Investor Verification Checklist
- Verify the actual closing date and final proceeds of the Second Placement (expected June 5, 2023).
- Confirm the post-closing share count and dilution impact on existing shareholders.
- Review the definitive Subscription Agreements for specific terms of the $64 million raise.
- Monitor the execution of the Share Option Award Agreement with Amit Munshi.
- Check subsequent filings for the updated 2023 Equity Incentive Plan document (Exhibit 10.1).